Award

NIH Reporter #5R01AG065248-05

Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months

Recipient

Cognition Therapeutics, Inc.

Award Amount

$16,494,670.00

Ceiling

$16,494,670.00

Awarded

August 25, 2026

Identifier

5R01AG065248-05

The project funds a Phase 2 clinical trial of CT1812, a candidate Alzheimer’s disease therapy, to assess safety and effects on cognition and disease-related biomarkers in early-stage patients.

Description

A randomized, double-blind, placebo-controlled Phase 2 trial evaluating the safety, tolerability, and efficacy of two doses of CT1812 in patients with early Alzheimer's disease over 18 months.

View original record